Masaru Matsuda, See Remark at Arcutis Biotherapeutics, Inc. (ARQT), sold 5,016 shares at $8.74 ($44K) on 2024-05-02, disclosed to the SEC on 2024-05-03.
Scheduled sale ($44k) by See Remark under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ARQT | SELL | 2026-08-05 | $32K | — | Filing → |
| ARQT | SELL | 2026-05-06 | $192K | — | Filing → |
| ARQT | SELL | 2026-03-03 | $314K | — | Filing → |